New cystic fibrosis medicine added to PBS

A better quality of life is now in reach under the Morrison Government’s plan to subsidise a life-changing cystic fibrosis medicine (Orkambi®), which significantly extends the lives of patients while saving families up to $250 000 a year.

Member for Gilmore, Ann Sudmalis said, “Under the Coalition Government’s investment, patients will now only pay a maximum of $39.50 per script, with concessional patients paying just $6.40.”

From the start of September all eligible patients can access the medicine immediately with Vertex agreeing to our request to provide compassionate free access until the medicine is listed on the on the PBS on 1 October.

“Since coming into Government, the Coalition has helped improve the health of Australians by subsidising more than $9 billion worth of new medicines.”

“Unlike Labor, we are subsidising all drugs recommended by the independent medical experts. We are now listing a new or amended medicine on the PBS on average, every day of the year.”

Orkambi® will be available on the Pharmaceutical Benefits Scheme (PBS) from 1 October 2018 for all patients over the age of 6 years.

Cystic fibrosis is a progressive, genetic disease that causes persistent lung infections and limits the ability to breathe over time. A defective gene causes a thick, sticky build- up of mucus in the lungs, pancreas, and other organs. Orkambi has been shown to slow the rate of decline in lung function and reduce the number of infections in people with cystic fibrosis.